About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingNCT07230080

Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer

The goal of this clinical trial is to evaluate whether sequential transarterial chemoembolization (TACE) followed by stereotactic body radiotherapy (SBRT) combined with targeted immunotherapy is effec...

Lead sponsor: Nanfang Hospital, Southern Medical University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Nanfang Hospital, Southern Medical University

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age ≥ 18 years
•Unresectable hepatocellular carcinoma (HCC)
•CNLC stage IIb-IIIb
•Target lesion(s) not previously treated with local therapy
•Child-Pugh class A5-B7 liver function
•Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2
•At least one measurable lesion based on modified RECIST (mRECIST) criteria

Exclusion Criteria

•Diagnosis of any malignant disease other than primary liver cancer within 3 years prior to enrollment
•Currently participating in another interventional clinical study
•History of allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation
•Presence of any severe or uncontrolled systemic disease
•Any medical history, comorbid condition, treatment, or abnormal laboratory finding that may interfere with study results or hinder full participation, or any other situation that the investigator considers inappropriate for enrollment
•Investigator's judgment of other potential risks making the patient unsuitable for participation in this study

Related studies

Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma

NCT07610551 · HCC - Hepatocellular Carcinoma

RECRUITINGPhase 3

DEB-TACE vs cTACE in HCC After TIPS

NCT07322848 · Hepatocellular Carcinoma (HCC), TACE, and more

RECRUITINGPhase 2

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

NCT07521852 · HCC - Hepatocellular Carcinoma

RECRUITINGPhase 2/3

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

NCT07426094 · Prostate Cancer, Brachytherapy, and more

RECRUITINGPhase 2

The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer

NCT06738160 · NSCLC, Stereotactic Body Radiation Therapy (SBRT), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 17, 2025Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

Phase—

Enrollment17

Start dateSep 2024

Last updatedNov 17, 2025

Condition

HCC - Hepatocellular Carcinoma SBRT TACE Immunotherapy Targeted Therapy

Locations shown

Nanfang Hosptial

Guangzhou

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 17, 2025Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions